Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;27(1):10-6.
doi: 10.3892/or.2011.1488. Epub 2011 Oct 4.

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

Affiliations

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

Lyndsay V Rhodes et al. Oncol Rep. 2012 Jan.

Abstract

The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TSA suppression of MCF-7TN-R cell clonogenic survival. MCF-7TN-R cells were plated (2,000 cells/well) in 10% DMEM in 6-well plates and allowed to adhere overnight. Twenty-four hours later the cells were treated with vehicle (DMSO) or TSA (0.1, 1, 10 μM) for 10 days. Colonies of ≥50 cells were counted as positive. Bars represent mean percentage clonogenic survival normalized to DMSO control cells ± SEM. (**p<0.01).
Figure 2
Figure 2
TSA regulation of microRNA expression in MCF-7TN-R. Heatmap of microRNA changes induced by treatment with TSA (10 μM) after 24 h in MCF-7TN-R cells. microRNAs demonstrating statistically significant changes in expression are shown (p<0.01). Green indicates down-regulated expression and red indicates up-regulated expression of microRNAs. Individual samples are represented in columns while specific microRNAs are represented by rows as labeled.

References

    1. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316–7339. - PubMed
    1. Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA. 1992;89:11538–11542. - PMC - PubMed
    1. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2009;27:542–549. - PubMed
    1. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and functional correlates. Genes Dev. 2006;20:3215–3231. - PubMed
    1. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics. 2008;9:1879–1902. - PMC - PubMed

Publication types

MeSH terms